Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, 50139 Florence, Italy.
Int J Mol Sci. 2022 Apr 20;23(9):4529. doi: 10.3390/ijms23094529.
The transient receptor potential ankyrin 1 (TRPA1), a member of the TRP superfamily of channels, is primarily localized in a subpopulation of primary sensory neurons of the trigeminal, vagal, and dorsal root ganglia, where its activation mediates neurogenic inflammatory responses. TRPA1 expression in resident tissue cells, inflammatory, and immune cells, through the indirect modulation of a large series of intracellular pathways, orchestrates a range of cellular processes, such as cytokine production, cell differentiation, and cytotoxicity. Therefore, the TRPA1 pathway has been proposed as a protective mechanism to detect and respond to harmful agents in various pathological conditions, including several inflammatory diseases. Specific attention has been paid to TRPA1 contribution to the transition of inflammation and immune responses from an early defensive response to a chronic pathological condition. In this view, TRPA1 antagonists may be regarded as beneficial tools for the treatment of inflammatory conditions.
瞬时受体电位锚蛋白 1(TRPA1)是 TRP 超家族通道的成员,主要定位于三叉神经、迷走神经和脊神经根神经节的初级感觉神经元亚群中,其激活介导神经源性炎症反应。TRPA1 在固有组织细胞、炎症和免疫细胞中的表达,通过对一系列细胞内途径的间接调节,协调一系列细胞过程,如细胞因子的产生、细胞分化和细胞毒性。因此,TRPA1 途径被认为是一种保护机制,可在各种病理条件下(包括几种炎症性疾病)检测和响应有害因子。人们特别关注 TRPA1 对炎症和免疫反应从早期防御反应向慢性病理状况转变的贡献。在这种观点中,TRPA1 拮抗剂可被视为治疗炎症性疾病的有益工具。